Hunter Syndrome News and Research

RSS
Hunter syndrome, or mucopolysaccharidosis Type II, is a lysosomal storage disease caused by a deficient (or absent) enzyme, iduronate-2-sulfatase (I2S).
The syndrome is named after physician Charles A. Hunter (1873-1955), who first described it in 1917. Born in Scotland, Hunter emigrated to Canada and had a medical practice in Winnipeg, Manitoba.
Gene editing within a living person for the first time

Gene editing within a living person for the first time

Shire launches awareness campaign to improve lives of people with rare MPS

Shire launches awareness campaign to improve lives of people with rare MPS

FDA clears Sangamo BioSciences' SB-318 IND application for treatment of MPS I

FDA clears Sangamo BioSciences' SB-318 IND application for treatment of MPS I

Synageva announces submission of Kanuma application to Cofepris for treatment of LAL Deficiency

Synageva announces submission of Kanuma application to Cofepris for treatment of LAL Deficiency

FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

Renaissance in drug development for rare diseases

Renaissance in drug development for rare diseases

GSK, Angiochem to develop and commercialize LSD treatments

GSK, Angiochem to develop and commercialize LSD treatments

Lentigen receives NIH STTR grant for Hunter syndrome lentiviral gene therapy

Lentigen receives NIH STTR grant for Hunter syndrome lentiviral gene therapy

Genetic Disorder Tracker introduced by Guidepoint Global

Genetic Disorder Tracker introduced by Guidepoint Global

Shire announces third quarter 2009 financial results

Shire announces third quarter 2009 financial results

Carnegie Mellon researchers to develop new stem cell-based drug delivery therapy

Carnegie Mellon researchers to develop new stem cell-based drug delivery therapy

Genzyme receives Japanese marketing approval for Elaprase

Genzyme receives Japanese marketing approval for Elaprase

First treatment for Hunter disease

First treatment for Hunter disease

FDA approves Elaprase (idursulfase) for Hunter syndrome

FDA approves Elaprase (idursulfase) for Hunter syndrome